secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001818331-25-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M
--------------------------------------------------------------------------------

- Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).
- Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.
- Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.
- FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.
- Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/0001818331-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/wgs-20250218.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer